In this piece, we discuss the 7 Mid-Cap Stocks With the Highest Gains in April.
Investors are increasingly turning to mid-cap stocks in a market shaped by geopolitical risk, sticky inflation, and rising energy costs.
On April 28, 2026, Reuters reported that Americans are extremely dissatisfied with the rising cost of living and the ongoing war with Iran. This has resulted in a decline in President Trump’s approval rating to 34%, the lowest of his current term. Gasoline prices in the U.S have risen more than 40% since the February 28 attack.
Amid that backdrop, small and mid-cap U.S. equities (SMIDs) remain the top choice for Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company.
On April 8, 2026, Reuters reported that Stucky sees opportunity rather than risk, driven by SMIDs’ continuously improving earnings estimates, cyclical nature, and attractive valuation discount to large-cap stocks. With the 10-year Treasury yield climbing from roughly 3.90% to 4.40%, he argued these conditions strengthen rather than undermine the case for selective positioning.
With that background in mind, let’s now jump to our list of the mid-cap stocks with the highest gains in April.
Photo by Adam Nowakowski on Unsplash
Our Methodology
To curate our list for this article, we identified stocks that recorded the strongest gains in April. We then ranked these stocks in ascending order by their share price performance for the month as of April 28, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. Soleno Therapeutics, Inc. (NASDAQ:SLNO)
After surging 57.56% so far in April, Soleno Therapeutics, Inc. (NASDAQ:SLNO) secures a spot on our list of the mid-cap stocks with the highest gains in April.
On April 6, 2026, Neurocrine, an American biopharmaceutical company, announced the acquisition of Soleno Therapeutics, Inc.. After the announcement, Soleno shares surged nearly 33% in early trading. Neurocrine cited the commercial potential of Soleno’s newly launched rare-disease therapy, Vykat XR.
Following that deal, however, on April 17, Wells Fargo downgraded Soleno Therapeutics, Inc. from “Overweight” to “Equal Weight.”
At the same time, other investment firms like Cantor Fitzgerald and RBC Capital viewed the move positively. Cantor projected Vykat XR to surpass $1 billion in annual revenue by 2029, with the therapy already generating about $190 million in 2025 sales within nine months of its March 2025 approval. Meanwhile, RBC Capital said the acquisition serves as the addition of a “third leg to the story that plays into Neurocrine’s current capabilities.”
However, analysts at Wells Fargo believe the transaction, which is expected to close in Q3 2026, leaves limited room for further upside. Accordingly, the firm trimmed its price target on Soleno Therapeutics, Inc. from $110 to $53.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases, including Prader-Willi Syndrome.
6. Dave Inc. (NASDAQ:DAVE)
With a 60.54% gain in April, Dave Inc. (NASDAQ:DAVE) has secured a spot on our list of the mid-cap stocks with the highest gains in April.
On April 10, 2026, as part of a larger Q1 results preview across its fintech coverage, Citizens increased its price target on Dave Inc. to $335 from $310 while maintaining an “Outperform” rating. The firm agreed that managing sector-wide volatility remains the biggest obstacle, with conditions in some areas of the capital markets stronger than in the broader markets.
Since Dave Inc. is a consumer fintech with an AI-driven credit model rather than a capital markets-exposed business, it is essentially shielded from the institutional trading dynamics that Citizens pointed out. This framing actually works to Dave’s advantage.
Joseph Vafi of Canaccord boosted his target to $328 from $274 in March, citing outsized growth and margin performance that notably exceeded both Dave Inc.’s own projection and the fintech industry as a whole. Those numbers may have laid the foundation for April’s surge.
Revenue for the entire year of 2025 increased by 60% to $554 million, while adjusted EBITDA increased by 162% to $227 million at a 41% margin, almost double the initial forecast. With record adjusted EBITDA of $72.3 million at a 45% margin, Q4 alone generated revenue of $163.7 million, up 62% year over year. While CashAI v5.5 significantly reduced delinquency rates, monthly transacting member growth increased for a third straight quarter.
Keefe Bruyette also raised Dave Inc.’s target from $250 to $295, indicating above-consensus 2026 forecasts of $690–$710 million in revenue and $290–$305 million in adjusted EBITDA.
Dave Inc. is a fintech company offering banking, budgeting, and small cash advance services through its mobile app to help users manage finances and avoid overdraft fees.
5. Sigma Lithium Corporation (NASDAQ:SGML)
With a 67.83% gain in April, Sigma Lithium Corporation (NASDAQ:SGML) has secured a spot on our list of the mid-cap stocks with the highest gains in April.
Source: pexels
On April 2, 2026, BofA upgraded Sigma Lithium’s stock to “Buy,” raising its price target from $14 to $17. This carries significant weight for a stock facing one of the harshest commodities cycles in recent memory. A $50 million prepayment agreement was signed in conjunction with Q4 earnings, which BofA noted as the pivotal moment. This agreement would give Sigma Lithium Corporation confidence to overcome its short-term liquidity crisis, resume regular operations, and accelerate Phase 2 capital spending alongside the ongoing Phase 1 ramp.
Due to a purposeful mining restructure, full-year 2025 production of high-grade premium lithium oxide was 183,000 tons, a 24% decrease from 2024. By turning dry stack tailings into high-purity lithium fines, Sigma Lithium Corporation was able to overcome the drop in volume and generate an extra 70,000 tons in revenue value. Operating cash flow increased 35% sequentially to $31 million in Q4 as a result of annual and quarterly cost reductions of 21% and 77%, respectively. Additionally, the company significantly strengthened its balance sheet by repaying 35% of its overall debt and 60% of its short-term debt during the year.
A $96 million working capital offtake for 2026 deliveries further supports near-term operations, while the $50 million prepayment, which covers 40,000 tons annually over three years, directly reduces the financial overhang that had caused investors to be cautious.
Sigma Lithium Corporation projects $218 to $260 million in free cash flow at current lithium pricing from Phase 1 alone, with Phase 2 capacity potentially doubling output. BofA’s increased conviction shows a company that has quietly strengthened its financial foundation while the market was focused elsewhere.
Sigma Lithium Corporation engages in the exploration and development of lithium deposits in Brazil, through which it serves the lithium-ion battery supply chain for the EV industry.
4. Navitas Semiconductor Corporation (NASDAQ:NVTS)
After surging 108.67% so far in April, Navitas Semiconductor Corporation (NASDAQ:NVTS) secures a spot on our list of the mid-cap stocks with the highest gains in April.
The most recent spark occurred on April 13, 2026, when Gregory M. Fischer, a seasoned semiconductor engineer, was named an independent director by Navitas Semiconductor Corporation with immediate effect.
Fischer is currently on the board of Semtech and has over 40 years of experience in the semiconductor industry, including a period as general manager and senior vice president at Broadcom. As a Class III director up for re-election in 2027, he will serve on Navitas’ Executive Steering and Compensation committees. That reflects a long-term strategic appointment.
Board Chairman Richard Hendrix put it simply: Greg is joining at a vital juncture, and his background is an invaluable asset for management as Navitas Semiconductor Corporation navigates a fiercely competitive, rapidly evolving market.
In relation to what Navitas Semiconductor Corporation internally refers to as its “Navitas 2.0” shift into high-power GaN and SiC markets, Fischer himself described the moment as a significant opportunity to accelerate the company’s transformation as it capitalizes on the AI revolution.
A month earlier, that shift had already been demonstrated.
Navitas Semiconductor Corporation unveiled its 800 V-6 V DC-DC power delivery board at NVIDIA GTC 2026 in San Jose on March 16, 2026. This product completely eliminates the conventional 48V intermediate bus converter by converting directly from 800 V to 6 V in a single stage. The board is specifically designed for NVIDIA’s 800 VDC data center infrastructure and growing MGX architecture. It delivers up to 96.5% peak efficiency at a 1 MHz switching frequency with a power density of 2,100 W/in³.
Reduced losses, increased board space, and more computation, memory, and GPU real estate are all benefits of fewer conversion stages.
Navitas Semiconductor Corporation is a leader in next-generation power semiconductors, focusing on gallium nitride (GaN) and silicon carbide (SiC) technologies that enable faster, more efficient power conversion. Founded in 2014 and headquartered in Torrance, California, the company went public in 2021. Its technologies are critical for high-growth applications, including electric vehicles, renewable energy systems, fast charging, and data centers. As global demand for energy efficiency intensifies and electrification trends accelerate, Navitas is positioned at the center of a multi-decade shift toward advanced power solutions.
3. Organon & Co. (NYSE:OGN)
After surging 119.70% so far in April, Organon & Co. secures a spot on our list of the mid-cap stocks with the highest gains in April.
On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co., a U.S. drugmaker, in an all-cash transaction with an estimated value of $11.75 billion, including debt. This acquisition marks the largest overseas acquisition by an Indian pharmaceutical company. The closing is anticipated to occur in early 2027, and Sun Pharma, India’s largest pharmaceutical company by market value ($40 billion), will pay $14.00 per share, a premium of over 24% to Organon’s April 24 closing price.
The strategic rationale is readily apparent: Sun is expanding its focus to higher-margin specialty drugs in obesity, oncology, and dermatology in order to overcome the decline in U.S. generic sales, which are further impacted by changing tariff regulations.
With $6.2 billion in sales at 30% EBITDA margins, Sun’s revenue and EBITDA will double as a result of the acquisition. Furthermore, Nuvama Wealth Management’s analyst Shrikant Akolkar projects that by FY28, it will be 30%–40% EPS accretive.
The main overhang is Organon & Co.’s net debt of over $8.6 billion. However, with Sun’s solid balance sheet and dedicated bank financing, Akolkar anticipates that the concerns will subside by year three. Beyond financial gains, Sun gains entry into biosimilars, a portfolio of more than 70 general and women’s health medications in almost 140 countries, and significant access to China, Brazil, and other emerging markets where its presence has been restricted.
Sun Pharma’s shares rose 7%, while Organon & Co.’s shares surged 16% in premarket trade.
On April 28, 2026, Piper Sandler upgraded Organon & Co. from “Underweight” to “Neutral” with a $14 price target. The firm highlighted the transaction as “lightning in a bottle” and acknowledged that it was surprising that a buyer showed up, given its assessment of Organon’s asset quality. Citing the early 2027 close, BofA concurrently changed its rating to No Rating, stating that shares are no longer trading on fundamentals.
Organon & Co. is a global healthcare company spun off from Merck in 2021, focused on women’s health, biosimilars, and established medicines. It is based in New Jersey and operates in over 140 countries.
2. Aehr Test Systems, Inc. (NASDAQ:AEHR)
With a 138.62% gain so far in April, Aehr Test Systems, Inc. (NASDAQ:AEHR) has secured a spot on our list of the mid-cap stocks with the highest gains in April.
That surge in Aehr Test Systems, Inc.’s share price reflects recent developments that highlight strong demand across hyperscale AI and silicon photonics markets. The company appears to be gaining momentum as a key enabler of AI infrastructure, as it announced a record $41 million follow-on production order from its lead hyperscale AI customer for package-level burn-in (PLB) of custom AI processor ASICs. Those chips are used in data center AI training and inference.
According to the management, the order is the largest in Aehr Test Systems, Inc.’s history and takes second-half fiscal 2026 bookings beyond the $92 million mark. Management had earlier guided for $60 million to $80 million in second-half fiscal 2026 bookings.
And there is more to it, as the same customer has already placed an initial Sonoma order for its higher-power next-generation AI accelerator ASIC, which is scheduled to enter production later this year. Therefore, the same customer is creating potential for additional demand growth in fiscal 2027. Prior to this win, in late March, Aehr Test Systems, Inc. secured a major silicon photonics customer as well.
Aehr Test Systems, Inc. designs, markets, manufactures, and sells test and burn-in equipment used in the semiconductor industry. The company’s products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures.
1. MaxLinear, Inc. (NASDAQ:MXL)
With a 197.01% gain so far in April, MaxLinear, Inc. (NASDAQ:MXL) has secured a spot on our list of the mid-cap stocks with the highest gains in April.
On April 24, 2026, MaxLinear, Inc. published its first quarter 2026 financial results, featuring revenue of $137.2 million (+1% QoQ). Reacting to the results, Stifel raised its price targets to $49 from $34 while reaffirming its “Buy” rating.
As evident from the results, data center optical interconnects are quickly becoming MaxLinear’s most powerful growth engine.
Analysts drew confidence from MaxLinear, Inc.’s strong results, which were driven by accelerating data center demand.
MaxLinear, Inc. revised its 2026 optical data center sales target to $150 million to $170 million from a prior range of $110 million to $130 million. That optimism reflects Keystone platform ramps across major U.S. and Asian customers, 1.6T platform sampling in anticipation of late-2026 production readiness, and an expected recovery in the Broadband segment.
More importantly, management’s projection for the June-quarter revenue of $165.0 million stole the spotlight, as it came 20.3% above the prior quarter and surpassed Stifel’s estimate by 18.7%, defying the historical seasonal softness of negative 2.4%.
Following the results, Needham also upgraded its rating on MaxLinear, Inc. to “Buy” from “Hold” on April 24, while reiterating a $60 price target. The firm anticipates that this business mix shift, combined with improving cash flow generation, will drive further share price appreciation, notwithstanding the ongoing Silicon Motion arbitration risk.
MaxLinear Inc. provides communications systems-on-chip solutions in the US, Asia, Europe, and internationally. It serves electronics distributors, module makers, OEMs, and original design manufacturers.
READ NEXT: 12 Best Warren Buffett Stocks to Invest in Now and 10 Stocks Under $5 That Will Explode.
